In conclusion, HR can improve the prognosis of patients with intermediate-stage HCC who satisfy the new HR criteria consisting of the up-to-seven criteria, serum albumin level >35 g/L, and serum AFP level <100 μg/L. The gene discussed is ALB; the disease is hepatocellular carcinoma.